AAA Mérieux and Shire back NeuroPhage

Mérieux and Shire back NeuroPhage

NeuroPhage Pharmaceuticals, a US-based developer of drugs for Alzheimer’s disease, has raised $12.4m in its series B round led by Mérieux Développement, the quasi-corporate venturing unit of France-based holding company Institut Mérieux.

Ireland-based drugs group Shire also participated in the round, while its $7m A round angel investors also reinvested in the company treating plaques (pictured).

Valérie Calenda, partner at Mérieux Développement, which plans to invest €70m ($100m) as a minority shareholder in third parties between 2010 and 2013, will join NeuroPhage’s board and Michael Heartlein, vice-president of research at Shire Human Genetic Therapies, will be a board observer.

Leave a comment

Your email address will not be published. Required fields are marked *